Corsair Pharma has successfully completed the?preclinical program?for its?TRX-248 Transdermal System, a once-daily patch designed to improve treatment for?Pulmonary Arterial Hypertension (PAH). This innovative transdermal system delivers an inert prodrug of?treprostinil, a key therapy in PAH management, providing steady and continuous blood levels with the convenience of a single daily application. With positive results from preclinical studies, Corsair is gearing up for its?Phase 1 human trial in Quarter 2, 2025—bringing us one step closer to a?more patient-friendly PAH treatment. This marks a significant milestone in the fight against this rare disease, and we look forward to seeing the impact of this next-generation therapy! https://lnkd.in/grxEHypb #PAHTreatment #CorsairPharma #Innovation #Healthcare #BioPharma
关于我们
Corsair Pharma is developing transformative solutions to improve the therapeutic profile of medications and provide superior treatment options for patients. The company is focused on the development of novel prodrugs of treprostinil to treat patients with PAH using a once-daily transdermal patch.
- 网站
-
https://www.corsairpharma.com
Corsair Pharma的外部链接
- 所属行业
- 制药业
- 规模
- 2-10 人
- 总部
- Sunnyvale，California
- 类型
- 私人持股
地点
-
主要
获取路线
1230 Bordeaux Dr
US，California，Sunnyvale，94089